Dry Eye Syndrome Treatment Market

Dry Eye Syndrome Treatment Market Outlook (2024 to 2034)

The global dry eye syndrome treatment market size is anticipated to be worth US$ 4,027.2 million in 2024. According to projections, the economy will grow steadily at a CAGR of 7.2% until 2034, and is expected to expand to an astounding size of US$ 10,961.2 million by 2034.

The eye's inability to lubricate or nourish itself due to inadequate tear quality is known as Dry Eye Syndrome or Keratoconjunctivitis Sicca. Symptoms include redness, stinging, a burning sensation, light sensitivity, watery eyes, stringy mucus, and blurred vision. The rising prevalence of these conditions has shown the market growth in the global dry eye syndrome treatment sector.

Key Market Growth Drivers

• Professionals in healthcare facilities are adopting more treatments for dry eye syndrome due to the aging population, pollution, screen time, and environmental factors driving up demand for these treatments.
• Healthcare manufacturers are providing various diagnostic tools to meet patient needs, driving the growing demand for efficient treatments for dry eye syndrome.
• The demand for dry eye treatments is rising due to increased patient awareness, which has prompted manufacturers to start consumer education campaigns.
• The demand for treatments for dry eye syndrome is growing due to factors like air conditioning, increased pollution, and other aspects of modern lifestyles that are replacing traditional ways of living.

Increased public and private awareness-raising campaigns, improved infrastructure, and growing medical expenses impact the dry eye syndrome treatment market.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 4,027.2 million
Forecasted Market Value (2034F)	US$ 10,961.2 million
Global Market Growth Rate (2024 to 2034)	7.2% CAGR
Artificial Tears Segment Growth Rate (2024 to 2034)	7.4%
Retail Pharmacies Segment Growth Rate (2024 to 2034)	7.9%
North America Market Share (2024)	40.4%
East Asia Market Share (2024)	9.7%
Key Companies Profiled	Allergen plc. (Abbvie) Novartis AG Otsuka Pharmaceuticals Co., Ltd. Bausch Health Companies, Inc. Akron, Inc. Johnson & Johnson, Inc. Thea Pharmaceuticals Limited OASIS Medical Altaire Pharmaceuticals Inc. Boiron USA Similasan Corporation Scope Ophthalmics Ltd. Reckitt Benckiser Group PLC Medicom Healthcare Ltd FDC Limited. Lupin Limited Jamjoom Pharmaceuticals Co. Sentiss Pharma Private Limited

Which Factors Have Driven the Global Surge in the Dry Eye Syndrome Treatment Industry?

“Advancements in Healthcare Infrastructure Boost the Market Growth”

The global industry for treatments for dry eye syndrome is expanding significantly due to several factors. Increasing healthcare costs is one of the leading causes, as it helps to improve infrastructure. Additionally, efforts are being made by both public and private organizations to raise awareness of dry eye syndrome, which should lead to further market expansion.

The market is expanding due to rising standards of care and increasing disposable income. However, the market dynamics are challenged by shifting dietary habits and sedentary lifestyles. Nevertheless, during the projected period, the growing elderly population and increasing awareness of dry eye issues are anticipated to accelerate the market's growth rate.

“Advance Ocular Surface Disorder Remedies Nurtures the Global Dry Eye Remedy Sector”

The significant rise in this condition's prevalence worldwide is one of the critical factors that favorably affect the global market. Most of these long-term illnesses change with age. However, due to rising screen usage, poor diet, rising contact lens use, and an increase in LASIK procedures, the prevalence is growing among the younger and geriatric demographics.

The goal of biotechnology and pharmaceutical companies working in the eye-care sector is to use their innovations to create treatments that work by funding research and development.

Throughout the forecast period, the dry eye syndrome market will extend owing to a rise in the demand for more potent treatment options for this condition.

Which Factors Present Challenges to the Dry Eye Syndrome Treatment Market Growth?

“Global Dry Eye Industry Faces Economic Challenges”

The global dry eye syndrome remedy sector is overrun with prescription goods, and price competition keeps prices low.

A multitude of people still require therapy for dry eye disease because of ignorance and lack of understanding. These issues are limiting the need for treatments for dry eye conditions.

Dry eye syndrome treatments vary in response, potentially slowing market expansion. The rapid growth of many therapies may limit the use of dry eye syndrome medicines.

Getting regulatory approval takes a lot of work. Larger budgets are required by several businesses to comply with regulatory bodies and slowing market expansion.

Many people use traditional self-care techniques combined with home remedies to treat their dry eye condition, reducing the need for professional treatment.

Country-wise Insights

The North American dry eye syndrome treatment industry is expected to rise at an astonishing 7.2% CAGR by 2034. The main factor fueling the expansion is the rising demand for eye care therapies in significant nations like the United States and Canada. By 2024, dry eye care products are predicted to hold a 74.7% market share in the United States. The market for treatments for dry eye conditions in East Asia is anticipated to increase, with a compound annual growth rate of 8.3% by 2034. As of 2024, China commands 46.1% of the East Asian eye care treatment market, making it the region's dominant force.

Why is the United States Dominating the Global Dry Eye Syndrome Treatment Market?

“Prescribed Eye Care Products Prospers in the United States Dry Eye Industry”

From 2024 to 2034, the United States is predicted to see a CAGR of 7.1%. In 2024, the sector is expected to have a substantial 74.7% of the global dry eye syndrome treatment market share, valued at US$ 1,651 million. Dry eye syndrome treatment is becoming increasingly in demand because of the growing number of people with the condition, the general population, and the rise in gaming and other virtual activities. The market size is significantly increased by the extensive healthcare systems in the United States, which prioritize patients' preferences for specific medicines.

Furthermore, a growing percentage of people use smartphones, tablets, and other cutting-edge gadgets, while most work with computers. The United States government and private enterprises may use advanced innovation during this period to turn the challenges brought on by disease into opportunities.

The United States biotechnology, pharmaceutical, and research sectors are working on advanced treatments for dry eye syndrome, with the FDA allowing medical prescriptions and eye treatments to boost market income. Healthcare product manufacturers are offering cost-effective solutions to improve patient outcomes.

Which Factors Position China as a Thriving Global Dry Eyes Disease Market?

“Novel Cost Efficient Ocular Surface Disorder Remedies Rumbles in China”

The East Asian dry eye therapy market is projected to reach a value of over US$ 529 million and a revenue share of 9.7% by 2034, growing at an 8.3% CAGR. With a predicted 46.1% revenue and a total value of US$ 244 million in 2024, the Chinese dry eye syndrome treatment market is expected to have a sizable market share. The sector is expected to grow at a CAGR of 10.1% until 2034, showing substantial opportunity for enterprises and investors.

Rising concerns about eye problems, increasing air pollution, and changing lifestyles are contributing to the expansion of China's dry eye syndrome treatment market. The rapidly surging healthcare systems, high-quality treatments, and experts are increasingly adopting dry eye syndrome treatment.

Patients prefer dry eye treatment to improve their conditions and treat disorders. Healthcare manufacturers offer cost-effective solutions for patients with dry eye syndrome with advanced care. Market players collaborate with research institutions to develop new therapies and medications to improve patient outcomes, fueling the Chinese market.

Key companies are vital in offering healthcare services with their specialized medical and affordable treatments for their patients. China's government seeks to invest a vast amount in healthcare infrastructure to offer improved and cost-effective treatment to patients that satisfy their needs.

Category-wise Insights

Fact.MR.'s market forecasts state that in 2024, artificial tears solutions are likely to hold a 60.6% market share. In addition, it is anticipated that cyclosporine eye drops has a sizeable 16.8% of the market.

Additionally, by 2024, the retail pharmacy industry is anticipated to command a sizeable proportion of 61.1% of the dry eye condition treatment market, based on its distribution channel. Furthermore, hospital pharmacies are expected to have a sizable 22.4% market share in the worldwide dry eye sector by 2034.

Why Dry Eye Syndrome Treatment Industry Experience a Surge in Demand for Organic Dry Eye Syndrome Treatment?

“Artificial Tears Solutions Wipes the Global Demand”

The artificial tears market leads the worldwide market based on product type, with a 60.6% market share in 2024. The meibomian gland dysfunction therapy industry is predicted to have a substantial demand for artificial tear solutions, with a consumption value estimated to reach US$ 3,311.2 million by 2024.

Artificial tears are becoming more extensively used to treat dry eye disease, according to medical professionals and eye care facilities. Patients seeking relief from moderate to mild dry eye conditions increasingly request artificial tears. These tears improve medical care that is reasonably priced and appeals to patients' interests.

Certain types of artificial tears assist the eye's healing, while others function to reduce the rate at which tears evaporate. A thickening agent keeps the solution on the eyes' surface for longer. It has been shown that artificial tears are the best substitute for managing mild cases of dry eyes.

Healthcare producers provide a wide variety of artificial tears, including gel-based ones for patients with certain dry eyes, which significantly accelerates the dry eye syndrome treatment market growth. Artificial tears are becoming increasingly popular due to changing lifestyles and increased environmental pollution, which causes dry eye syndrome.

Competitive Landscape

The market for primary dry eye disease treatments is growing at a rapid pace, and leading businesses are concentrating on diversifying their product offerings by conducting in-depth research, development, and product releases. These businesses are creating cutting-edge manufacturing facilities and making strategic agreements with mid-sized or small-sized competitors to increase their market presence.

Major industry participants are investing in significant research and development to provide creative solutions to enhance their goods. In addition, these businesses are implementing various marketing tactics, including partnerships, mergers, acquisitions, and new product releases, to boost their worldwide market revenue and maintain an advantage over their competitors.

• In December 2023, Dr. Damon Dierker spoke about the potential of sutureless cryopreserved amniotic membrane therapy for moderate to severe dry eye, emphasizing its three-month durability and efficacy.
• In November 2023, Pepose Vision Institute's medical director, Jay Pepose, announced a new dry eye treatment that targets neurotrophic and neurosensory aspects, reducing symptoms in high-frequency patients.
• In June 2023, Novaliq GmbH acquired FDA approval for VEVYE 0.1%, a cyclosporine ophthalmic solution, for the treatment of dry eye symptoms.
• In May 2023, the FDA approved MIEBO, a treatment for dry eye disease that targets tear evaporation, developed by Bausch + Lomb Corporation and Novaliq GmbH, making it the first FDA-approved solution for DED.

Segmentation of Dry Eye Syndrome Treatment Market

• By Product Types :

  • Cyclosporine
  • Topical Corticosteroids
  • Artificial Tears
  • Punctal Plugs
  • Oral Omega Supplements
  • Others

• By Distribution Channel :

  • Hospital Pharmacies
  • Eye Health Clinics
  • Retail Pharmacies
  • Online Pharmacies

• By Region :

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa